Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN026 plus HB1801 vs Trastuzumab/Pertuzumab/Docetaxel in HER2+ Breast Cancer
NCT05838066Phase 3Recruiting
- Sponsor
- Shanghai Jinmante Biotechnology Co., Ltd.
- Start
- Jul 2023
- Primary completion
- Jul 2025
- Modality
- Small Molecules, Nanoparticles, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of anbenitamab, albumin-bound docetaxel in HER2-positive breast cancer, sponsored by Shanghai Jinmante Biotechnology Co., Ltd.. Started Jul 2023; status: recruiting.
02
Drugs
anbenitamabalbumin-bound docetaxel
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT05838066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05838066.